ResearcherHospital Universitario La PazActive in the last 2 years

Ismael Ghanem

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1859-0737; OpenAlex author ID A5080476285. Sources: OpenAlex.

Their work

Papers: 9
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 29

Papers, trials and grants by year

2021: 1 paper · 2022: 3 papers · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper

Papers 9

Prognostic modeling of overall survival in metastatic pancreatic cancer: an inflammation-based tool validated in PANTHEIA-SEOM cohort. Co-author DOI 10.1007/s12094-026-04554-8 ↗
Real-world management and outcome of patients with pancreatic adenocarcinoma. Results of the Spanish RETUD gastrointestinal registry. Co-author DOI 10.1016/j.esmorw.2025.100116 ↗
Real-world effectiveness and safety of second- or third-line pegylated liposomal irinotecan plus 5-fluorouracil and folinic acid in pancreatic ductal adenocarc… Co-author DOI 10.1177/17588359241309828 ↗
Cytokines and Pancreatic Ductal Adenocarcinoma: Exploring Their Relationship with Molecular Subtypes and Prognosis. Co-author DOI 10.3390/ijms25179368 ↗
The Relationship between the Expression of GATA4 and GATA6 with the Clinical Characteristics and Prognosis of Resectable Pancreatic Adenocarcinoma. Co-author DOI 10.3390/biomedicines11020252 ↗
Neoadjuvant chemotherapy with or without radiotherapy versus upfront surgery for resectable pancreatic adenocarcinoma: a meta-analysis of randomized clinical t… Co-author DOI 10.1016/j.esmoop.2022.100485 ↗
Identification of Carcinogenesis and Tumor Progression Processes in Pancreatic Ductal Adenocarcinoma Using High-Throughput Proteomics. Co-author DOI 10.3390/cancers14102414 ↗
Cytokines and Lymphoid Populations as Potential Biomarkers in Locally and Borderline Pancreatic Adenocarcinoma. Co-author DOI 10.3390/cancers14235993 ↗
Prognostic factors in advanced pancreatic ductal adenocarcinoma patients-receiving second-line treatment: a single institution experience. Co-author DOI 10.1007/s12094-021-02589-7 ↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Jaime Feliú · 6 shared papers, 2021–2024 · strength 0.91
- Paper Cytokines and Pancreatic Ductal Adenocarcinoma: Exploring Their Relationship with Molecular Subtypes and Prognosis. DOI 10.3390/ijms25179368 ↗
- Paper Neoadjuvant chemotherapy with or without radiotherapy versus upfront surgery for resectable pancreatic adenocarcinoma: … DOI 10.1016/j.esmoop.2022.100485 ↗
- Paper The Relationship between the Expression of GATA4 and GATA6 with the Clinical Characteristics and Prognosis of Resectabl… DOI 10.3390/biomedicines11020252 ↗
Roberto Pazo-Cid · 3 shared papers, 2022–2025 · strength 0.52
- Paper Real-world effectiveness and safety of second- or third-line pegylated liposomal irinotecan plus 5-fluorouracil and fol… DOI 10.1177/17588359241309828 ↗
- Paper Real-world management and outcome of patients with pancreatic adenocarcinoma. Results of the Spanish RETUD gastrointest… DOI 10.1016/j.esmorw.2025.100116 ↗
- Paper Cytokines and Lymphoid Populations as Potential Biomarkers in Locally and Borderline Pancreatic Adenocarcinoma. DOI 10.3390/cancers14235993 ↗
Laura Gutiérrez-Sainz · 3 shared papers, 2021–2024 · strength 0.49
- Paper Cytokines and Pancreatic Ductal Adenocarcinoma: Exploring Their Relationship with Molecular Subtypes and Prognosis. DOI 10.3390/ijms25179368 ↗
- Paper The Relationship between the Expression of GATA4 and GATA6 with the Clinical Characteristics and Prognosis of Resectabl… DOI 10.3390/biomedicines11020252 ↗
- Paper Prognostic factors in advanced pancreatic ductal adenocarcinoma patients-receiving second-line treatment: a single inst… DOI 10.1007/s12094-021-02589-7 ↗
Victoria Heredia-Soto · 3 shared papers, 2022–2024 · strength 0.48
- Paper Cytokines and Pancreatic Ductal Adenocarcinoma: Exploring Their Relationship with Molecular Subtypes and Prognosis. DOI 10.3390/ijms25179368 ↗
- Paper The Relationship between the Expression of GATA4 and GATA6 with the Clinical Characteristics and Prognosis of Resectabl… DOI 10.3390/biomedicines11020252 ↗
- Paper Identification of Carcinogenesis and Tumor Progression Processes in Pancreatic Ductal Adenocarcinoma Using High-Through… DOI 10.3390/cancers14102414 ↗
Teresa Mercade Macarulla · 2 shared papers, 2025 · strength 0.40
- Paper Real-world effectiveness and safety of second- or third-line pegylated liposomal irinotecan plus 5-fluorouracil and fol… DOI 10.1177/17588359241309828 ↗
- Paper Real-world management and outcome of patients with pancreatic adenocarcinoma. Results of the Spanish RETUD gastrointest… DOI 10.1016/j.esmorw.2025.100116 ↗
Javier Gallego-Plazas · 2 shared papers, 2022–2026 · strength 0.35
- Paper Prognostic modeling of overall survival in metastatic pancreatic cancer: an inflammation-based tool validated in PANTHE… DOI 10.1007/s12094-026-04554-8 ↗
- Paper Cytokines and Lymphoid Populations as Potential Biomarkers in Locally and Borderline Pancreatic Adenocarcinoma. DOI 10.3390/cancers14235993 ↗
Lucía Trilla‐Fuertes · 2 shared papers, 2022–2023 · strength 0.28
- Paper The Relationship between the Expression of GATA4 and GATA6 with the Clinical Characteristics and Prognosis of Resectabl… DOI 10.3390/biomedicines11020252 ↗
- Paper Identification of Carcinogenesis and Tumor Progression Processes in Pancreatic Ductal Adenocarcinoma Using High-Through… DOI 10.3390/cancers14102414 ↗
Ángela Lamarca Lete · 1 shared paper, 2026 · strength 0.23
- Paper Prognostic modeling of overall survival in metastatic pancreatic cancer: an inflammation-based tool validated in PANTHE… DOI 10.1007/s12094-026-04554-8 ↗
Alberto Carmona‐Bayonas · 1 shared paper, 2026 · strength 0.23
- Paper Prognostic modeling of overall survival in metastatic pancreatic cancer: an inflammation-based tool validated in PANTHE… DOI 10.1007/s12094-026-04554-8 ↗
Vilma Pacheco-Barcía · 1 shared paper, 2026 · strength 0.23
- Paper Prognostic modeling of overall survival in metastatic pancreatic cancer: an inflammation-based tool validated in PANTHE… DOI 10.1007/s12094-026-04554-8 ↗
Elena Brozos-Vázquez · 1 shared paper, 2026 · strength 0.23
- Paper Prognostic modeling of overall survival in metastatic pancreatic cancer: an inflammation-based tool validated in PANTHE… DOI 10.1007/s12094-026-04554-8 ↗
Carmen Guillén‐Ponce · 1 shared paper, 2026 · strength 0.23
- Paper Prognostic modeling of overall survival in metastatic pancreatic cancer: an inflammation-based tool validated in PANTHE… DOI 10.1007/s12094-026-04554-8 ↗
Rafael Álvarez-Gallego · 1 shared paper, 2025 · strength 0.21
- Paper Real-world effectiveness and safety of second- or third-line pegylated liposomal irinotecan plus 5-fluorouracil and fol… DOI 10.1177/17588359241309828 ↗
Joaquina Martínez-Galán · 1 shared paper, 2025 · strength 0.21
- Paper Real-world effectiveness and safety of second- or third-line pegylated liposomal irinotecan plus 5-fluorouracil and fol… DOI 10.1177/17588359241309828 ↗
Fernando Garicano Goldaraz · 1 shared paper, 2025 · strength 0.21
- Paper Real-world effectiveness and safety of second- or third-line pegylated liposomal irinotecan plus 5-fluorouracil and fol… DOI 10.1177/17588359241309828 ↗
Antonio Cubillo · 1 shared paper, 2025 · strength 0.21
- Paper Real-world effectiveness and safety of second- or third-line pegylated liposomal irinotecan plus 5-fluorouracil and fol… DOI 10.1177/17588359241309828 ↗
Andrés Jesús Muñoz Martín · 1 shared paper, 2025 · strength 0.18
- Paper Real-world management and outcome of patients with pancreatic adenocarcinoma. Results of the Spanish RETUD gastrointest… DOI 10.1016/j.esmorw.2025.100116 ↗
Florian Castet · 1 shared paper, 2025 · strength 0.18
- Paper Real-world management and outcome of patients with pancreatic adenocarcinoma. Results of the Spanish RETUD gastrointest… DOI 10.1016/j.esmorw.2025.100116 ↗
Berta Laquente · 1 shared paper, 2025 · strength 0.18
- Paper Real-world management and outcome of patients with pancreatic adenocarcinoma. Results of the Spanish RETUD gastrointest… DOI 10.1016/j.esmorw.2025.100116 ↗
Ana Fernández Montés · 1 shared paper, 2025 · strength 0.18
- Paper Real-world management and outcome of patients with pancreatic adenocarcinoma. Results of the Spanish RETUD gastrointest… DOI 10.1016/j.esmorw.2025.100116 ↗
Alfredo Carrato Mena · 1 shared paper, 2025 · strength 0.18
- Paper Real-world management and outcome of patients with pancreatic adenocarcinoma. Results of the Spanish RETUD gastrointest… DOI 10.1016/j.esmorw.2025.100116 ↗
Eva Martínez de Castro · 1 shared paper, 2025 · strength 0.18
- Paper Real-world management and outcome of patients with pancreatic adenocarcinoma. Results of the Spanish RETUD gastrointest… DOI 10.1016/j.esmorw.2025.100116 ↗
Enrique Aranda Aguilar · 1 shared paper, 2025 · strength 0.18
- Paper Real-world management and outcome of patients with pancreatic adenocarcinoma. Results of the Spanish RETUD gastrointest… DOI 10.1016/j.esmorw.2025.100116 ↗
Iranzu González‐Borja · 1 shared paper, 2022 · strength 0.13
- Paper Cytokines and Lymphoid Populations as Potential Biomarkers in Locally and Borderline Pancreatic Adenocarcinoma. DOI 10.3390/cancers14235993 ↗
Joaquín Fernández‐Irigoyen · 1 shared paper, 2022 · strength 0.13
- Paper Cytokines and Lymphoid Populations as Potential Biomarkers in Locally and Borderline Pancreatic Adenocarcinoma. DOI 10.3390/cancers14235993 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.